Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Operations (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Cash from Operations data on record, last reported at 18787000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 14.99% year-over-year to 18787000.0; the TTM value through Sep 2025 reached 58214000.0, up 30.76%, while the annual FY2024 figure was 72027000.0, 53.53% up from the prior year.
  • Cash from Operations reached 18787000.0 in Q3 2025 per BTAI's latest filing, down from 12575000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12043000.0 in Q1 2025 and bottomed at 52353000.0 in Q1 2023.
  • Average Cash from Operations over 4 years is 27051933.33, with a median of 26863000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: plummeted 61.52% in 2023, then skyrocketed 66.18% in 2024.
  • A 4-year view of Cash from Operations shows it stood at 38639000.0 in 2022, then soared by 30.48% to 26863000.0 in 2023, then soared by 44.87% to 14809000.0 in 2024, then dropped by 26.86% to 18787000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 18787000.0 in Q3 2025, 12575000.0 in Q2 2025, and 12043000.0 in Q1 2025.